When Trauma Goes Deeper Than the Brain: The Immune System and PTSD

Today, post-traumatic stress disorder (PTSD) is perceived primarily as a mental health condition — involving flashbacks, anxiety, avoidance, and constant tension. But research in recent years shows that PTSD is not only about the psyche. It is also about the body, which seems to get stuck in a state of alarm, and about the immune system, which reacts to trauma just as powerfully as the brain. New work from researchers at Texas A&M University draws attention to precisely this hidden layer: how trauma reconfigures both the innate and the adaptive immune systems.

The immune system as a mirror of trauma

We are used to thinking that the immune system protects us from infections and repairs tissues after injury. But its capabilities are not limitless. When it comes to skin, where simply forming a scar is sufficient, the mechanism works. However, with more complex organs — the brain, heart, kidneys — such ‘crude repairs’ lead to chronic dysfunction. And if you add prolonged stress and psychotrauma to this, the immune system is faced with a task for which it is evolutionarily unprepared.

Normally, the immune system is divided into two wings. The first is innate — fast and universal, consisting of macrophages, neutrophils, and other cells. It reacts instantly but does not remember the experience. The second is adaptive — represented by T- and B-lymphocytes, which are capable of forming a “memory.” It is these that make vaccination possible and allow the body to respond in a targeted way. In recent years, it has turned out that the boundary between these two systems is blurred: even the innate immune system is capable of “learning” and enhancing its response to repeated challenges. This discovery has provided new ground for hypotheses about why PTSD becomes so deeply embedded in our physiology.

During a trauma, it is not just the psyche that is engaged, but also the sympathetic nervous system — the very same ‘fight or flight’ mechanism. In the short term, it helps us to survive. But with chronic arousal, it triggers an avalanche: immune cells receive signals, produce pro-inflammatory molecules called cytokines, and the level of inflammation remains elevated. And it is important to stress here: in people with PTSD, this inflammatory state does not disappear even when psychotherapy alleviates the behavioural symptoms.

When inflammation does not subside

Studies show that patients with PTSD have consistently elevated levels of cytokines such as IL-6, TNF-α, and C-reactive protein. These molecules not only reflect inflammation but also directly affect the brain — they increase anxiety, interfere with emotion regulation, and create a persistent sense of threat. Moreover, an elevated level of IL-6 correlates with the intensity of symptoms: the higher the inflammation, the stronger the fear and avoidance.

This presents an alarming point: traditional approaches relieve the behavioural manifestations but do not necessarily normalise the immune markers. In other words, psychological work improves the condition, but the body remains in an inflamed state. This supports data showing that veterans or disaster survivors, even after successful treatment, have an increased risk of cardiovascular and autoimmune diseases.

At the cellular level, the picture is even more ambiguous. Some studies show an increase in the number of monocytes and a decrease in the activity of natural killer (NK) cells, while others record their suppression. The role of microglia — the immune cells of the brain — is even more debated. In animals, their activation is associated with anxiety and cognitive impairment, and blocking them improves behaviour. But in human studies, the picture is more complex: some patients even show an ‘anti-inflammatory’ response from microglia, suggesting different phases and scenarios in the course of PTSD.

We must also consider the adaptive immune system. Patients with PTSD more often show a shift towards activated T-cells and a decrease in the number of ‘naïve’ and regulatory cells, while the proportion of memory cells increases. In other words, the body seems to be stuck in a “war-ready” mode. This reconfiguration enhances the overall inflammatory state and reinforces long-term risks.

What this means for therapy and the future

Today, clinicians treat PTSD primarily as a psychological disorder. But if we take the immune component into account, new horizons open up. Methods are already being tested that combine psychotherapy with interventions targeting inflammation — from vagus nerve stimulation to the use of antibodies that block key cytokines like IL-6. In animal experiments, such approaches not only reduced inflammation levels but also decreased anxiety and social avoidance.

This leads to an important conclusion: PTSD should be considered not only as a psychiatric diagnosis but also as a systemic illness, where the psyche and the immune system are in constant dialogue. Perhaps this is the key to explaining why some people recover from trauma more quickly, while others are plunged into chronic suffering.

The researchers emphasise the need for longitudinal studies, starting from the moment of trauma. A great deal is missed when analysis is limited to a clinical diagnosis. Ideally, patients should be monitored from the first days after an event, recording not only psychological manifestations but also immune markers. Such an approach would allow for the early identification of at-risk groups and the development of preventive measures.

Today, we see that PTSD is not just about flashbacks, nightmares, and anxiety. It is also a subtle but destructive reconfiguration of the immune system that can undermine health for years. Psychotherapy alleviates suffering, but it does not always change the physiological landscape. Does this mean that the future of trauma treatment must extend beyond psychiatry to include integrated work with the body? And are we ready to view mental health conditions as systemic diseases of the entire organism?